Table 2.
Demographic characteristics of the study population
| Study group | Control group | |
|---|---|---|
| No. (%) of patients | 26 (55) | 32 (45) |
| Men (%) | 13 (50) | 8 (25) |
| Women (%) | 13 (50) | 24 (75) |
| Age at time of imaging (y), median (IQR) | 40 (27–51) | 37 (28–47) |
| Disease duration (y), median (IQR) | 7 (4–11) | 7 (3–21) |
| Days between endoscopy and MRI, median (IQR) | 13 (7–23) | 11 (4–20) |
| Previous surgery, no. (%) of patients | 16 (62) | 22 (69) |
| Maintenance therapy, no. (%) of patients | 18 (69) | 23 (72) |
| Antitumor necrosis factor, no. (%) of patients | 5 (19) | 11 (34) |
| Steroids, no. (%) of patients | 8 (31) | 3 (9) |
| Immunosuppressant, no. (%) of patients | 12 (46) | 12 (38) |
| 5-Aminosalicylic acid medications, no. (%) of patients | 1 (4) | 7 (22) |
| Vedolizumab, no. (%) of patients | 1 (4) | 0 |
| Presence of fistula (on MRI) | ||
| None, no. (%) of patients | 3 (12) | 8 (25) |
| Simple, no. (%) of patients | 11 (42) | 16 (50) |
| Complex, no. (%) of patients | 12 (46) | 8 (25) |
| Endoscopy diagnosis | ||
| Absence of lesions, no. (%) of patients | 0 | 32 (100) |
| Non-ulcerative lesions, no. (%) of patients | 7 (27) | 0 |
| Ulcerations, no. (%) of patients | 19 (73) | 0 |
IQR interquartile range